Home > Insider Trading > Filing (0001070081-18-000056)

Filing Details

Accession Number:: 0001070081-18-000056
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-21 16:33:04
Reporting Period:: 2018-06-19

Accepted Time:: 2018-06-21 16:33:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070081	Ptc Therapeutics Inc.	PTCT	Pharmaceutical Preparations (2834)	043416587

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578850	Gregory Neil Almstead	C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080	Evp Research Pharma Ops & Tech	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-06-19	20,000	$10.85	37,154	No	4	M	Direct
Common Stock	Disposition	2018-06-19	8,000	$48.09	29,154	No	4	S	Direct
Common Stock	Disposition	2018-06-19	12,000	$48.46	17,154	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right To Buy)	Disposition	2018-06-19	20,000	$10.85	20,000	$10.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
46,898		2023-05-15	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,125	Indirect	By spouse

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right To Buy)	$451.20	2019-05-15	200	200	Direct
Common Stock	Stock Option (Right To Buy)	$1,149.60	2020-02-02	200	200	Direct
Common Stock	Stock Option (Right To Buy)	$490.80	2021-04-27	216	216	Direct
Common Stock	Stock Option (Right To Buy)	$218.40	2022-01-10	166	166	Direct
Common Stock	Stock Option (Right To Buy)	$10.85	2023-05-15	3,102	3,102	Direct
Common Stock	Stock Option (Right To Buy)	$27.05	2024-01-27	40,000	40,000	Direct
Common Stock	Stock Option (Right To Buy)	$51.00	2025-01-01	69,550	69,550	Direct
Common Stock	Stock Option (Right To Buy)	$30.86	2026-01-03	55,000	55,000	Direct
Common Stock	Stock Option (Right To Buy)	$11.23	2027-01-02	35,000	35,000	Direct
Common Stock	Stock Option (Right To Buy)	$18.01	2028-01-02	70,000	70,000	Direct
Common Stock	Stock Option (Right To Buy)	$508.80	2019-10-07	12	12	Indirect
Common Stock	Stock Option (Right To Buy)	$1,149.60	2020-02-02	1	1	Indirect
Common Stock	Stock Option (Right To Buy)	$490.80	2021-04-27	7	7	Indirect
Common Stock	Stock Option (Right To Buy)	$218.40	2022-01-10	7	7	Indirect
Common Stock	Stock Option (Right To Buy)	$27.05	2024-01-27	1,300	1,300	Indirect
Common Stock	Stock Option (Right To Buy)	$51.00	2025-01-01	2,060	2,060	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2019-05-15	200	200	Direct
2020-02-02	200	200	Direct
2021-04-27	216	216	Direct
2022-01-10	166	166	Direct
2023-05-15	3,102	3,102	Direct
2024-01-27	40,000	40,000	Direct
2025-01-01	69,550	69,550	Direct
2026-01-03	55,000	55,000	Direct
2027-01-02	35,000	35,000	Direct
2028-01-02	70,000	70,000	Direct
2019-10-07	12	12	Indirect
2020-02-02	1	1	Indirect
2021-04-27	7	7	Indirect
2022-01-10	7	7	Indirect
2024-01-27	1,300	1,300	Indirect
2025-01-01	2,060	2,060	Indirect

Footnotes

The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.58 to $48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.38 to $48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Currently exercisable.
This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.